Trial Profile
A Randomized Phase II Trial of Weekly Gemcitabine, Paclitaxel and External Irradiation (50.4 GY) Followed by the Farnesyl Transferase Inhibitor R115777 (NSC702818) for Locally Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2020
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 13 Apr 2010 Actual end date (1 Mar 2010) added as reported by ClinicalTrials.gov record.
- 13 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Sep 2005 New trial record.